Verastem, Inc. (VSTM)

Market Cap	485.73M +81.9%
Revenue (ttm)	30.91M +209.1%
Net Income	-209.47M
EPS	-3.02
Shares Out	87.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,828,392
Open	5.74
Previous Close	5.82
Day's Range	5.44 - 5.91
52-Week Range	4.01 - 11.25
Beta	0.39
Analysts	Strong Buy
Price Target	15.00 (+171.25%)
Earnings Date	Mar 4, 2026

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM
• Website: https://www.verastem.com

Financial Performance

In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 171.25% from the latest price.

Price Target

$15.0

(171.25% upside)

Analyst Consensus: Strong Buy